Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Vivid MedComms bolster their business with a new senior appointment

A new hire for Vivid MedComms, part of the Lucid Group of companies

Lucid Group Communications Limited

Evolve and thrive vs wait and wither

What is the future of your marketing function?

Sanofi reception

After some big setbacks, Sanofi talks up its R&D portfolio

Hopes its pipeline of 71 projects delivers strong sales

- PMLiVE

Gilead adds to CAR-T assets with Cell Design Labs buyout

Gains full control of the biotherapeutics firm following its acquisition of Kite Pharma

- PMLiVE

GSK gets another approval for Nucala in US

Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease

- PMLiVE

New NHS Alliance launches healthcare TV programme

In Search of Wellness follows those on a quest to improve healthcare

- PMLiVE

Millennials’ disappointing medicine habits

Survey finds only 60% of 18-34 years olds take treatments as prescribed

Andy Busch joins Shire as its CSO and head of research and development

And Howard Mayer is promoted to chief medical officer

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links